FPRX Five Prime Therapeutics, Inc.

29.79
-0.69  -2%
Previous Close 30.48
Open 30.57
Price To book 2.38
Market Cap 831.05M
Shares 27,897,000
Volume 255,269
Short Ratio 5.89
Av. Daily Volume 436,321

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dose expansion phase initiated May 2016. Completion of enrollment announced April 10, 2017. Data due at ASCO June 4, 2017. Abstract 11078.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
FP-1039
Mesothelioma cancer

Latest News

  1. ETFs with exposure to Five Prime Therapeutics, Inc. : May 23, 2017
  2. Five Prime Welcomes Garry Nicholson to Board of Directors
  3. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
  4. Five Prime Therapeutics posts 1Q loss
  5. Five Prime Announces First Quarter 2017 Results and Provides Business Update
  6. Investor Network: Five Prime Therapeutics, Inc. to Host Earnings Call
  7. Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting
  8. Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4
  9. Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)
  10. Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting
  11. Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting
  12. Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR Annual Meeting
  13. ETFs with exposure to Five Prime Therapeutics, Inc. : March 27, 2017
  14. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  15. Five Prime Therapeutics Announces Executive Changes
  16. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017
  17. Edited Transcript of FPRX earnings conference call or presentation 23-Feb-17 9:30pm GMT

SEC Filings

  1. 8-K - Current report 17853426
  2. 8-K - Current report 17844417
  3. 8-K - Current report 17838601
  4. S-8 - Securities to be offered to employees in employee benefit plans 17818773
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17816017
  6. 8-K - Current report 17814107
  7. 8-K - Current report 17814030
  8. DEF 14A - Other definitive proxy statements 17727848
  9. 8-K - Current report 17702075
  10. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17634659